Table 4.
Comparison of baseline characteristics between patients with and without improvement in fibrosis after long-term antiviral treatment
| With improvement in fibrosis | Without improvement in fibrosis | P-value | |
| n | 24 | 18 | |
| Male gender, n (%) | 17 (70.83) | 13 (72.22) | 0.9215 |
| Age (mean ± SD), yr | 43.8 ± 9.9 | 42.9 ± 9.8 | 0.7596 |
| log10 HBV DNA (mean ± SD), IU/mL | 6.7 ± 1.2 | 5.9 ± 1.5 | 0.0602 |
| ALT (mean ± SD), U/L | 102 ± 82 | 99 ± 121 | 0.6473 |
| HBeAg positivity, n (%) | 17 (70.83) | 10 (55.56) | 0.3065 |
| Median grade (range) | 10 (3-16) | 9 (0-13) | 0.1713 |
| Median stage (range) | 5 (3-6) | 3.5 (2-5) | 0.0230 |
| Treated with ETV, n (%) | 13 (54.17) | 6 (33.33) | 0.1795 |
| Treatment duration ≥ 24 mo, n (%) | 24 (100) | 13 (72.22) | 0.0101 |
HBV: Hepatitis B virus; ALT: Alanine aminotransferase; HBeAg: Hepatitis B e antigen; ETV: Entecavir.